I am a
Home I AM A Search Login

Papers of the Week


Papers: 11 Jun 2022 - 17 Jun 2022


Pharmacology/Drug Development


2022 Jun 10


Brain Behav

Real-world evidence following a mandatory treatment break after a 1-year prophylactic treatment with calcitonin gene-related peptide (pathway) monoclonal antibodies.

Authors

Nsaka M, Scheffler A, Wurthmann S, Schenk H, Kleinschnitz C, Glas M, Holle D
Brain Behav. 2022 Jun 10:e2662.
PMID: 35687795.

Abstract

Current German and European guidelines suggest migraine patients undertake a treatment break after 9 to 12 months of treatment with CGRP (pathway) monoclonal antibodies.